Quintiles Wins Pfizer Development Operations Strategic Supplier Excellence Award
RESEARCH TRIANGLE PARK, NC-Quintiles Transnational Corp. today announced that its Data Management division has received the 2008 Pfizer Development Operations’ Strategic Supplier Excellence Award.
Pfizer presents the award to their Development Operations Functional Service Providers (FSPs) that demonstrate consistent and excellent performance in four areas: quality; service delivery and reliability; innovation and business processes; and customer service and responsiveness.
“Quintiles has consistently demonstrated superior performance and partnership by working to reduce timelines and streamline processes, adding high value to the Data Management business,” said Rob Goodwin, Vice President of Global Clinical Data Services, Pfizer.
Quintiles executives said the value of the partnership is enhanced by the strength of the Pfizer-Quintiles relationship.
“The Pfizer and Quintiles teams have worked closely together to lock databases ahead of schedule, increase productivity and achieve cost savings,” said Theo Erasmus, Vice President, Global Data Management, Quintiles Africa, who heads the FSP with Pfizer. “A major reason for our successful relationship is proactive communication. By maintaining an open dialogue, we’ve been able to increase quality, improve processes and encourage innovation.”
“We are honored and delighted to be selected for this award because it recognizes what can be achieved through open, honest collaboration and teamwork,” said Paula Brown Stafford, Executive Vice President, Integrated Clinical Services, Quintiles. “We look forward to building an even stronger relationship with our colleagues at Pfizer and building on our successes for 2009.”
Quintiles supports Pfizer data management primarily from locations in Bloemfontein, South Africa and Bangalore, India.
About Quintiles
Quintiles is the only fully integrated biopharmaceutical services company offering clinical, commercial, consulting and capital solutions worldwide. The Quintiles network of 23,000 engaged professionals in more than 50 countries around the globe works with an unwavering commitment to patients, safety and ethics. Quintiles helps biopharmaceutical companies navigate risk and seize opportunities in an environment where change is constant. For more information, please visit www.quintiles.com.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
New Data Emerges from Phase IIb RELIEVE UCCD Study in Ulcerative Colitis and Crohn’s Disease
February 25th 2025Following initial positive results shared by Teva and Sanofi in December 2024, new data shows duvakitug (TEV’574/SAR447189) achieved higher rates of clinical remission compared to placebo in the advanced therapy-experienced subgroup.
